Evidence that faecal carriage of resistant *Escherichia coli* by 16-week-old dogs in the United Kingdom is associated with raw feeding and that *E. coli* from these dogs are shared with humans and cause opportunistic infections.

Oliver Mounsey[1*], Kezia Wareham[2*], Ashley Hammond[3], Jacqueline Findlay[1], Virginia C. Gould[1,2], Katy Morley[2], Tristan A. Cogan[2], Katy M.E. Turner[2,3], Matthew B. Avison[1‡#], Kristen K. Reyher[2‡]

[1]University of Bristol School of Cellular & Molecular Medicine, Biomedical Sciences Building, University Walk, Bristol. BS8 1TD.

[2]University of Bristol Veterinary School, Langford House, Langford, Bristol. BS40 5DU

[3]University of Bristol Medical School, Population Health Sciences, Canynge Hall, 39 Whatley Road, Bristol. BS8 2PS

***O.M. and K.W. contributed equally to this work.**

[‡]M.A. and K.R. contributed equally to this work.

#Correspondence: Matthew B. Avison, School of Cellular & Molecular Medicine, University of Bristol. Bristol BS8 1TD. United Kingdom. bimba@bris.ac.uk.

Abstract

We report a survey (August 2017 to March 2018) and risk factor analysis of faecal carriage of antibacterial-resistant (ABR) *Escherichia coli* in 223 sixteen-week-old dogs in the United Kingdom. Raw feeding was associated with the presence of *E. coli* resistant to fluoroquinolones, tetracycline, amoxicillin, and streptomycin, but not to cefalexin or cefotaxime. Whole genome sequencing of 30 fluoroquinolone-resistant (FQ-R), 22 cefotaxime-resistant (CTX-R) and seven dual FQ-R/CTX-R *E. coli* isolates showed a wide range of sequence types (STs), an approximately 50:50 split of CTX-M:AmpC-mediated CTX-R, and almost exclusively mutational FQ-R dominated by ST744 and ST162. Comparisons between *E. coli* isolates from puppies known to be located within a 50 x 50 km region with those isolated from human urinary tract and bloodstream infections (isolated in parallel in the same region) identified a clone of ST963 *E. coli* carrying chromosomal bla_{CMY-2} in two puppies and causing two urinary tract infections and one bloodstream infection. Furthermore, an ST744 FQ-R clone was carried by one puppy and caused one urinary tract infection. Accordingly, we conclude that raw feeding is associated with carriage of ABR *E. coli* in dogs even at sixteen weeks of age and that bacteria carried by these dogs are shared with humans and cause serious opportunistic infections. We therefore suggest that those who feed their dogs raw meat seriously consider the potential ABR-transmission threat their pet may become as a result and deploy appropriate hygiene practices in mitigation.

Introduction

Antimicrobial resistance and particularly antibacterial resistance (ABR) has many negative impacts on the health and welfare of humans and animals including increased morbidity and mortality and an increase in treatment costs (1). ABR is linked across human populations, animal populations and the environment, and it is possible for ABR bacteria - or ABR genes that they carry - to be passed between these realms (2). Previous research has indicated that farmed animals act as reservoirs of ABR bacteria that can be transmitted to humans either through the food chain, through direct contact between humans and animals or via the environment (3,4).

In many countries, particularly in urban areas, interaction between humans and farm animals – directly or via the environment – is limited. This may explain why studies using whole genome sequencing (WGS) have found little evidence that sharing of ABR bacteria between farmed animals and humans is a significant problem (5-8). However, close interaction between humans and domestic animals is common in such areas. Accordingly, it may be that for many people around the world, a pet dog is a more likely source of ABR bacteria than are farmed animals. Indeed, ABR bacteria found in domestic pets and their owners are often indistinguishable (9-12). A key ABR pathogen of relevance is *Escherichia coli*, which is carried in the intestines of humans, farmed and companion animals, and causes a significant disease burden in all three, and especially in humans (13).

There are several ways that dogs may become colonised by ABR *E. coli* and so bring them into the home. Ingestion is an essential part of colonisation; therefore, ingestion of faeces or faecally contaminated food or water by dogs may be a key

source of ABR bacteria derived from humans and farmed animals. For example, farm animal manure is often spread on pastureland where dogs might be exercised. Wastewater from farm run-off or from human sewage outlets may introduce *E. coli* to fresh and sea water where dogs might bathe (14,15). Meat can be contaminated with animal faeces during slaughter, and if eaten in its raw form by a dog, may lead to *E. coli* colonisation (16). Research has also suggested that dogs become colonised by ABR bacteria when visiting veterinary hospitals, which act as reservoirs for multi-drug resistant (MDR) organisms, and particularly if the dog receives antibacterial therapy (17-19). Recent research examining 374 veterinary practices in the UK estimated that during the two years investigated, around 25% of approximately one million pet dogs registered received at least one antibacterial course. Of dog antibacterial usage in this study, 60% was classified as use of a 'critically important' medicine as defined by WHO criteria (20).

Overall, ABR bacteria have been detected in both healthy and sick adult dogs and associations have been found between increased carriage of ABR bacteria and exposure to antibacterials (19). Associations have also been found between increased carriage of ABR bacteria following veterinary healthcare in general as well as with coprophagia and with the feeding of raw poultry (21-25). Of direct relevance to the present study, two UK studies have identified associations between ABR in faecal *E. coli* of adult dogs and those dogs being fed raw meat (21,24).

Up to now, there has not been any published work reporting very early life risk factors for carriage of ABR *E. coli* in domestic pet dogs. In the UK, current recommendations are for juvenile dogs to be weaned onto solid food and receive a core vaccination at six to eight weeks of age and then receive booster vaccinations every two to four weeks until 16 weeks of age (26). Dogs should stay with their

mother until eight weeks of age, and owners are usually advised not to walk their dog outside in public places until after the dog has had its second vaccination (approximately 12 weeks of age).

In this study, risk factors were investigated to explore associations between various lifestyle factors and the detection of ABR *E. coli* in faecal samples taken from dogs at 16 weeks of age. Practices and behaviours that might increase ingestion of faecal bacteria from the environment or food were particularly considered. Furthermore, WGS was used to characterise ABR isolates. The focus was specifically on resistance to critically important antibacterials: 3rd generation cephalosporins (3GC), e.g., cefotaxime (CTX) and fluoroquinolones. CTX resistant (CTX-R) and fluoroquinolone resistant (FQ-R) *E. coli* carried by a sub-set of puppies were compared with those cultured from human urinary tract and bloodstream infections collected in parallel within the same 50 x 50 km region, to investigate whether there is evidence of transmission.

Results and Discussion

Risk factors for carriage of ABR E. coli *in dogs at 16 weeks of age*

In total, 295 dogs were recruited and data for 223 dogs were included in the analysis. Submissions were excluded if the questionnaire was not fully completed (n=14) or because the faecal sample did not grow enough *E. coli* to be sure of ABR status as defined in Experimental (n=58). For each of the 223 included faecal samples, ABR *E. coli* carriage status was categorised as positive or negative for resistance to five test antibacterials: amoxicillin, cefalexin, ciprofloxacin, streptomycin, or tetracycline, as set out in Experimental. In a preliminary Chi-

118 squared analysis, the only significant risk factor identified for 16-week-old dogs
119 providing faecal samples carrying *E. coli* resistant to at least one antibacterial was
120 having been fed raw food (p <0.001; **Table 1**). Subsequent univariable and
121 multivariable logistic regression analyses showed a strong association between raw
122 feeding and carriage of *E. coli* resistant to any one of the five antibacterials tested as
123 well as individually with resistance to each of the antibacterials tested except
124 cefalexin (**Table 2**).

125 The most substantial risk associated with raw feeding in 16-week-old dogs was that
126 of carriage of FQ-R *E. coli* (**Table 2**). This association has previously been reported
127 in adult dogs in the UK; a study based on 445 dogs found that feeding raw poultry
128 significantly increased the risk of carrying FQ-R *E. coli* in faeces (22). Findings from
129 the present study extend these earlier studies to show that the impact of raw feeding
130 on ABR *E. coli* carriage can be seen as early as 10 weeks after the first introduction
131 of solid food. Faecal samples taken from broilers at a slaughterhouse commonly
132 contain FQ-R *E. coli* (27) and raw chicken imported into (28) and produced in the UK
133 (29) have been identified as contaminated with FQ-R *E. coli*. Feeding raw chicken
134 could therefore be a source of FQ-R *E. coli* in our study, as has been seen with adult
135 dogs (22), but this remains to be confirmed. The risk of dogs acquiring ABR bacteria
136 from meat would be mitigated simply by cooking that meat to reduce any
137 contamination with faecal bacteria that occurs at slaughter and during processing.

138

139 *Molecular epidemiology of CTX-R and FQ-R* E. coli *from puppies*

140 Of faecal samples from 34 dogs that contained cefalexin-resistant *E. coli*, 27 gave
141 CTX-R isolates. PCR analysis was used to identify mobile resistance genes

142 associated with CTX-R in these isolates; where the same PCR profile was seen for
143 multiple CTX-R isolates from a sample, a single isolate was taken forward for WGS
144 to represent that CTX-R type and sample. In total, 29 unique isolates from these 27
145 dogs were analysed by WGS. Of these, seven isolates were also FQ-R (**Table 3**).

146 WGS revealed a wide range of *E. coli* STs and CTX-R mechanisms (**Table 3**): ST88
147 (one isolate with CTX-M-1; three isolates with mutations in the *ampC* promoter
148 known to be associated with hyper-expression) was dominant, followed by ST744
149 (three FQ-R isolates with CTX-M-1), ST963 (three isolates with CMY-2) and ST38
150 (two isolates with CTX-M-15). Seventeen additional isolates, each representing a
151 unique ST, were found to be carrying CTX-M-1 (three isolates), CTX-M-15 (three
152 isolates), CTX-M-65 (one isolate), CTX-M-14 (one isolate), CMY-2 (three isolates)
153 DHA-1 (one isolate) and *ampC* promoter mutation (five isolates).

154 Overall, therefore, AmpC-type β-lactamase-mediated resistance was found in 15/29
155 isolates and CTX-M was found in 14/29. This approximately 50:50 split was also
156 seen in a recent analysis of CTX-R *E. coli* from 53 dairy farms in South West
157 England, where amoxicillin/clavulanate use was associated with finding AmpC-
158 mediated CTX-R *E. coli* in farm samples (8). A study examining prescribing at small
159 animal veterinary practices in the UK found that amoxicillin/clavulanate was the most
160 common antibacterial prescribed, accounting for 36% of prescriptions (30), and it has
161 been demonstrated that routine amoxicillin/clavulanate treatment selects for
162 increased CTX-R *E. coli* in the faeces of dogs (19). It could therefore be
163 hypothesised that the reason why clavulanic acid-insensitive AmpC-type β-
164 lactamases are so common in CTX-R *E. coli* carried by dogs is because of high
165 levels of amoxicillin/clavulanate usage in the canine population generally. However,
166 whilst this study did not record veterinary treatments, it seems unlikely that

antibacterial therapy was widespread in these puppies, given their age and exclusion of puppies that had been hospitalised. This finding of AmpC dominance is therefore suggestive of transmission into the juvenile dogs in the study. There was no positive association between raw feeding and the presence of CTX-R isolates in general; only six out of 29 CTX-R isolates were from raw-fed dogs (**Table 3**). However, among these, five out of eight of the AmpC hyper-producing isolates were from raw-fed dogs. Whilst these numbers are too small for clear conclusions to be drawn, it is plausible that raw feeding may selectively seed *ampC* hyper-producer *E. coli* carriage.

Carriage of FQ-R *E. coli* was strongly associated with raw feeding in puppies (**Table 2**). From 26 puppies that produced samples carrying FQ-R *E. coli*, 30 isolates were subjected to WGS (**Table 4**) in addition to the seven dual FQ-R/CTX-R isolates discussed above (**Table 3**). Plasmid-mediated quinolone resistance mechanisms (PMQR) were found in only 3/37 FQ-R isolates, and in only one ST58 isolate carrying *qnrS*1 and a single *gyrA* mutation (**Table 4**) was there any suggestion that a PMQR was necessary for conferring FQ-R. The other two PMQR-carrying FQ-R isolates were also CTX-R (**Table 3**). These two were an ST1196 isolate carrying *qnrS*1 and an ST1431 isolate carrying *qnrB*4, but in both there were also two mutations in *gyrA* and one in *parC*, sufficient to confer FQ-R in the absence of a PMQR gene (31). Indeed, many of the FQ-R isolates collected in this study carried identical mutations and no PMQR genes (**Table 4**). Interestingly, five of the CTX-R isolates that were not FQ-R also carried PMQRs: four had a *qnrS*1 gene and one ST38 isolate had an *aac(6)-Ib*-cr gene (**Table 3**). This would support previous conclusions that carriage of these genes is not sufficient to confer FQ-R in the absence of other mechanisms (31).

192 Of the FQ-R isolates sequenced, ST744 (12/37 isolates) dominated, with 6/37
193 isolates identified as ST162, 4/37 identified as ST1011, 3/37 identified as ST224,
194 2/37 identified as ST1196 and individual examples of 10 other STs (**Table 3, 4**).

195

196 *Evidence of faecal carriage of CTX-R and FQ-R* E. coli *in puppies also causing*
197 *urinary and bloodstream infections in humans in the same geographical area*

198 A phylogenetic analysis of all the CTX-R and FQ-R isolates from puppies subjected
199 to WGS in this study was constructed (**Figure 1**). There were three clusters of
200 isolates with chromosomal mutations conferring resistance: FQ-R isolates of ST162
201 and ST744 with multiple gyrase and topoisomerase mutations and a smaller ST88
202 cluster with chromosomal *ampC* promoter mutations conferring CTX-R and
203 amoxicillin/clavulanate resistance. In contrast, mobile resistance mechanisms were
204 spread widely across the phylogenetic tree. Notably, one FQ-R isolate was ST1193,
205 which is an important clone currently emerging in human infections and of the most
206 pathogenic phylogroup, B2 (32). It was therefore interesting to test relationships
207 between CTX-R and FQ-R isolates from locally recruited dogs with human urinary
208 CTX-R and FQ-R isolates from people living in the same geographical area as the
209 locally recruited dogs (33,34) whose infections occurred within the same six-month
210 period as collection of the canine faecal samples yielding these isolates.

211 There were four CTX-R isolates from locally recruited dogs; two of these (from two
212 different dogs: Dog 21 and Dog 22) were ST963; the others were ST88 and ST2179
213 (**Table 3**). None of the 225 CTX-R urinary *E. coli* (33) in the comparison was ST2179
214 and a SNP distance analysis showed that the canine ST88 isolate was >1000 SNPs
215 distant in the core genome from its closest ST88 human urinary isolate. A core

genome SNP distance of 30 or fewer is commonly seen in Enterobacteriales isolates that are confirmed to be part of an acute outbreak of foodborne illness (35). Hence, for these ST88 isolates, there was no evidence for sharing of isolates between dogs and humans. In contrast, the two canine ST963 isolates were 37 SNPs different from each other, suggesting recent sharing of the isolate. Significantly, however, the isolate from Dog 21 was <50 SNPs different from each of two human urinary ST963 isolates, and the isolate from Dog 22 was <65 SNPs from these same two human urinary isolates. Even more troubling, the isolate from Dog 21 was only 34 SNPs different from a CTX-R ST963 bloodstream isolate, one of 82 CTX-R bloodstream isolates collected in parallel from clinical cases in the same geographical region at the same time. The isolate from Dog 22 was 51 SNPs different from this bloodstream isolate. The urinary and bloodstream isolates were between 31 and 38 SNPs different from each other, so this is clear evidence for sharing of the human and canine CTX-R ST963 isolates. Each of these isolates (two canine, two urinary and one bloodstream) had a mobile bla_{CMY-2} gene embedded into the chromosome at the same position - proximal to *nhaRA*, *dnaJ* - which is further evidence of descent from a recent common ancestor. Most interestingly, another canine ST963 isolate was identified in this study, but not in a locally recruited dog (Dog 10, **Figure 1**). In this case, the isolate was 33, 35 and 21 SNPs different from the two urinary isolates and the bloodstream isolate, respectively, an even closer match than that seen with isolates from the two locally recruited dogs, suggesting even more recent sharing. Whilst Dog 10 was not locally recruited, it is possible that it could still be based locally as address details for the nationally recruited dogs were not available for analysis.

Of the seven FQ-R isolates from locally recruited puppies (**Table 3**, **Table 4**), five

were of STs found amongst 188 FQ-R urinary *E. coli* from people living in the same geographical area, isolated within six months of collection of the isolates from puppies (34). Of the canine isolates, one was ST10 and two each were ST744 and ST162 (**Table 4**). One of the ST744 isolates was 47 SNPs different from a human urinary isolate, which is suggestive of sharing, as defined above. Among the other four canine, the lowest SNP difference from a human isolate was 324, which does not suggest sharing in these cases. Interestingly, the puppy carrying the seemingly shared ST744 isolate, Dog 31, was the only FQ-R *E. coli* positive locally recruited dog reported to be fed raw meat (**Table 4**).

Conclusions

This study has identified raw meat feeding as a risk factor for the excretion of ABR *E. coli* in the faeces of 16-week-old puppies, with particularly strong impact on excretion of isolates resistant to the critically important fluoroquinolones. If owners insist on feeding raw meat to their dog, it is essential that they fully understand this practice puts their dog at risk of becoming colonised with bacteria resistant to critically important antibacterials.

E. coli is the most clinically important opportunistic human bacterial pathogen (13). ABR *E. coli* infections are more difficult to treat, and result in more morbidity and higher mortality rates (13); there is also strong evidence that domestic pet dogs transmit ABR bacteria to humans (9-12, 36,37) and this study provides clear evidence of the faecal carriage within puppies of CTX-R and FQ-R *E. coli* clonally related to those that have also caused urinary and bloodstream infections in humans living in the same geographical region collected within months of each other.

Therefore, if owners feed raw food to their dog, practices that mitigate the risk of onward transmission of ABR *E. coli* - which are more likely to be carried by these dogs - to humans should be encouraged. These include strict hygiene practices when anyone (particularly those vulnerable to bacterial infection) interacts with a raw-fed dog along with scrupulous disposal of the dog's faeces so that it cannot pose a risk to the general human population by contaminating the wider environment with ABR *E. coli*.

Experimental

Recruitment of the cohorts

Dog owners were recruited to take part in this study in two ways: (i) 236 were already recruited to the Dogs Trust "Generation Pup" project, a longitudinal study examining the health, welfare and behaviour of dogs across the UK (39) and (ii) 59 were locally recruited via word-of-mouth advertisement to clients bringing young dogs in for routine checks to veterinary practices in Somerset and Bristol, via puppy socialisation classes and via social media as well as local media advertisement. Locally recruited owners answered survey questions (listed in **Table 1**). As part of Generation Pup, owners completed more extensive surveys relating to their dogs at 16 weeks of age and responses to relevant survey questions (**Table 1**) were extracted from wider Generation Pup survey data. All dog owners also supplied a single faecal sample collected from their dog at 16 weeks of age. All dog owners were recruited between August 2017 and March 2018, and all owners gave consent. Ethical approval for this study was granted by the University of Bristol Health Sciences Student Research Ethics Committee (56783). Health status of the dogs

and prior veterinary treatment was not recorded for locally recruited dogs, and so was not included in the analysis. However, dogs that had been previously hospitalised were excluded.

Faecal samples and processing

All dog owners were supplied with a sample collection pack comprised of a specimen bottle, gloves, biohazard bag and a freepost envelope. Faecal samples were sent by post to the University of Bristol's Veterinary School alongside the consent form and, for locally recruited dogs, a questionnaire. To process each faecal sample, approximately 0.1-0.5 g of faeces was taken and weighed. Ten millilitres per gram of phosphate buffered saline (PBS) was added to the sample and the mixture vortexed. Next, 0.5 mL of the faecal/PBS homogenate was added to 0.5 mL of 50% v/v sterile glycerol and processed as below.

Testing for ABR bacteria

Data were collapsed into a binary "positive/negative" outcome for the homogenate derived from each faecal sample. ABR positivity was defined by the appearance (following 37°C overnight incubation) of blue/green *E. coli* colonies after spreading 20 µL of faecal homogenate (or a 10-fold dilution in PBS if inoculum effect was observed) onto Tryptone Bile X-Glucuronide (TBX) agar plates containing either 0.5 mg/L ciprofloxacin (to identify fluoroquinolone resistance [FQ-R]), 16 mg/L cephalexin, 8 mg/L amoxicillin, 16 mg/L tetracycline, or 64 mg/L streptomycin. Cefalexin-resistant isolates (up to five per plate) grown from primary processing of

312 faecal samples were sub-cultured onto agar plates containing 2 mg/L of cefotaxime
313 (CTX); isolates that grew were deemed CTX-R and taken forward for further testing.
314 These concentrations were chosen based on relevant human clinical breakpoints as
315 defined by the European Committee on Antimicrobial Susceptibility Testing (40).
316 Faecal homogenates were also plated onto non-antibiotic TBX agar and samples
317 were only included in the study if ≥10 *E. coli* cfu/µL were detected in an undiluted
318 faecal homogenate. Therefore, the limit of detection for ABR for all faecal
319 homogenates included in the analysis was ≤0.5% prevalence.

320

321 *Risk factor analysis*

322 Univariable and multivariable logistic regression models were used to evaluate
323 associations between ABR *E. coli* positivity in homogenates derived from faecal
324 samples and risk factors identified from the survey data (Stata/IC 15.1, StataCorp
325 LLC, College Station, TX, USA). A backward stepwise method was used. In this
326 method the full set of possible factors was analysed, with the least significant factors
327 removed one at a time until all remaining factors had *p*-values of 0.05 or less. For the
328 risk factor analysis, questionnaire answers were collapsed into binary 'Yes/No'
329 variables; questionnaire answers of 'sometimes', 'often', 'almost always' and
330 'frequently' were all categorised as 'Yes'.

331

332 *Isolates from human infections*

333 WGS data for 225 CTX-R and 188 FQ-R human urinary *E. coli* from a 50 x 50 km
334 region (including the homes of the 59 locally recruited dogs collected during the
335 same timespan as the collection of faecal samples from these puppies) has been

reported previously (33, 34). Eighty-two CTX-R *E. coli* bloodstream isolates from patients being treated at hospitals in this same geographical region were obtained from the regional microbiology diagnostic laboratory (Severn Pathology, Southmead Hospital, North Bristol NHS Trust). All infections occurred during the same period as puppy faecal sample collection for this study.

PCR and WGS analysis of CTX-R and FQ-R E. coli

Multiplex PCR assays were used to differentiate CTX-R puppy *E. coli* isolates carrying different β-lactamase genes, as described previously (33). WGS of deduplicated, representative CTX-R and FQ-R isolates from puppies, together with the human CTX-R bloodstream isolates was performed by MicrobesNG (https://microbesng.uk/) on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA) using 2x250 bp paired end reads. Reads were trimmed using Trimmomatic (41) and assembled into contigs using SPAdes (42) 3.13.0 (http://cab.spbu.ru/software/spades/). Contigs were annotated using Prokka (43). ABR genes were assigned using the ResFinder (44) and Sequence Types designated by MLST 2.0 (45) on the Centre for Genomic Epidemiology (http://www.genomicepidemiology.org/) platform. Single nucleotide polymorphism (SNP) distance analysis was performed using SNP-dists (https://github.com/tseemann/snp-dists).

Phylogenetic analysis

Sequence alignment and phylogenetic analysis was carried out using the Bioconda channel (46) on a server hosted by the Cloud Infrastructure for Microbial

Bioinformatics (CLIMB; 47). The reference sequence was *E. coli* ST131 isolate EC958 complete genome (accession: HG941718). Sequences were first aligned to a closed reference sequence and analysed for SNP differences, whilst omitting insertion and deletion elements, using the Snippy alignment program (https://github.com/tseemann/snippy). Alignment was then focused on regions of the genome common to all isolates (the "core genome") using the Snippy-core program, thus eliminating the complicating factors of insertions and deletions. Aligned sequences were then used to construct a maximum likelihood phylogenetic tree using RAxML utilising the GTRCAT model of rate heterogeneity and the software's autoMR and rapid bootstrap to find the best-scoring maximum likelihood tree and including tree branch lengths, defined as the number of base substitutions per site compared (48,49). Finally, phylogenetic trees were illustrated using the web-based Microreact program (50).

Acknowledgements

Genome sequencing was provided by MicrobesNG (http://www.microbesng.uk). The authors thank Dogs Trust and Rachel Casey, Jane Murray, Rachel Kinsman and Michelle Lord for assisting with data collection from the Generation Pup project participants included in this study. The authors are grateful to all puppy owners who took part in this study.

Funding

This work was funded by grant NE/N01961X/1 to MBA, TAC, KMT, KKR from the Antimicrobial Resistance Cross Council Initiative supported by the seven United Kingdom research councils. Dogs Trust fund the Generation Pup project.

The authors declare no conflicts of interest.

Author Contributions

Conceived the Study: K.K.R., M.B.A.

Collection of Data: K.W. O.M., J.F., K.M. supervised by T.A.C., M.B.A., K.K.R.

Cleaning and Analysis of Data: O.M. K.W. A.H., V.C.G., supervised by M.B.A., K.M.T., K.K.R.

Initial Drafting of Manuscript: K.W., O.M., K. K. R., M.B.A.

Corrected and Approved Manuscript: All Authors

References

1. Friedman ND, Temkin E, Carmeli Y. 2016. The negative impact of antibiotic resistance. Clin Microbiol Infect. 22:416-22.
2. Woolhouse M, Ward M, van Bunnik B, Farrar J. 2015. Antimicrobial resistance in humans, livestock and the wider environment. Philos Trans R Soc Lond B Biol Sci. 370:20140083.

402 3. Zurfluh K, Glier M, Hächler H, Stephan R. 2015. Replicon typing of plasmids
403 carrying *bla*$_{CTX-M-15}$ among Enterobacteriaceae isolated at the environment,
404 livestock and human interface. Sci Total Environ. 521-522:75-8.
405 4. Magouras I, Carmo LP, Stärk KDC, Schüpbach-Regula G. 2017. Antimicrobial
406 Usage and -Resistance in Livestock: Where Should We Focus? Front Vet Sci.
407 4:148.
408 5. Findlay J, Mounsey O, Lee WWY, Newbold N, Morley K, Schubert H, Gould VC,
409 Cogan TA, Reyher KK, Avison MB. 2020. Molecular Epidemiology of *Escherichia*
410 *coli* Producing CTX-M and pAmpC β-Lactamases from Dairy Farms Identifies a
411 Dominant Plasmid Encoding CTX-M-32 but No Evidence for Transmission to
412 Humans in the Same Geographical Region. Appl Environ Microbiol. 87:e01842-
413 20.
414 6. Day MJ, Rodríguez I, van Essen-Zandbergen A, Dierikx C, Kadlec K, Schink AK,
415 Wu G, Chattaway MA, DoNascimento V, Wain J, Helmuth R, Guerra B, Schwarz
416 S, Threlfall J, Woodward MJ, Coldham N, Mevius D, Woodford N. 2016. Diversity
417 of STs, plasmids and ESBL genes among *Escherichia coli* from humans, animals
418 and food in Germany, the Netherlands and the UK. J Antimicrob Chemother.
419 71:1178-1182.
420 7. Ludden C, Raven KE, Jamrozy D, Gouliouris T, Blane B, Coll F, de Goffau M,
421 Naydenova P, Horner C, Hernandez-Garcia J, Wood P, Hadjirin N, Radakovic M,
422 Brown NM, Holmes M, Parkhill J, Peacock SJ. 2019. One Health Genomic
423 Surveillance of *Escherichia coli* Demonstrates Distinct Lineages and Mobile
424 Genetic Elements in Isolates from Humans versus Livestock. mBio. 10:e02693-
425 18.
426 8. Alzayn M, Findlay J, Schubert H, Mounsey O, Gould VC, Heesom KJ, Turner KM,

427 Barrett DC, Reyher KK, Avison MB. 2020. Characterization of AmpC-
428 hyperproducing *Escherichia coli* from humans and dairy farms collected in
429 parallel in the same geographical region. J Antimicrob Chemother 75:2471-2479.
430 9. Toombs-Ruane LJ, Benschop J, French NP, Biggs PJ, Midwinter AC, Marshall
431 JC, Chan M, Drinković D, Fayaz A, Baker MG, Douwes J, Roberts MG, Burgess
432 SA. 2020. Carriage of extended-spectrum beta-lactamase-and AmpC beta-
433 lactamase-producing *Escherichia coli* from humans and pets in the same
434 households. Appl Environ Microbiol. 86:e01613-20.
435 10. Kidsley AK, White RT, Beatson SA, Saputra S, Schembri MA, Gordon D,
436 Johnson JR, O'Dea M, Mollinger JL, Abraham S, Trott DJ. 2020. Companion
437 Animals Are Spillover Hosts of the Multidrug-Resistant Human Extraintestinal
438 *Escherichia coli* Pandemic Clones ST131 and ST1193. Front Microbiol. 11:1968.
439 11. Hong JS, Song W, Park HM, Oh JY, Chae JC, Jeong S, Jeong SH. 2020.
440 Molecular Characterization of Fecal Extended-Spectrum β-Lactamase- and
441 AmpC β-Lactamase-Producing *Escherichia coli* From Healthy Companion
442 Animals and Cohabiting Humans in South Korea. Front Microbiol. 11:674.
443 12. Hong JS, Song W, Park HM, Oh JY, Chae JC, Shin S, Jeong SH. 2019. Clonal
444 Spread of Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae
445 Between Companion Animals and Humans in South Korea. Front Microbiol.
446 10:1371.
447 13. Adler A, Katz DE, Marchaim D. 2016. The Continuing Plague of Extended-
448 spectrum β-lactamase-producing Enterobacteriaceae Infections. Infect Dis Clin
449 North Am. 30:347-375.
450 14. Amos GC, Hawkey PM, Gaze WH, Wellington EM. 2014. Waste water effluent
451 contributes to the dissemination of CTX-M-15 in the natural environment. J

452 Antimicrob Chemother. 69:1785-91.
453 15. Leonard AFC, Zhang L, Balfour AJ, Garside R, Hawkey PM, Murray AK,
454 Ukoumunne OC, Gaze WH. 2018. Exposure to and colonisation by antibiotic-
455 resistant *E. coli* in UK coastal water users: Environmental surveillance, exposure
456 assessment, and epidemiological study (Beach Bum Survey). Environ Int.
457 114:326-333.
458 16. Schmidt M, Unterer S, Suchodolski JS, Honneffer JB, Guard BC, Lidbury JA,
459 Steiner JM, Fritz J, Kölle P. 2018. The fecal microbiome and metabolome differs
460 between dogs fed Bones and Raw Food (BARF) diets and dogs fed commercial
461 diets. PLoS One. 13:e0201279.
462 17. Gibson JS, Morton JM, Cobbold RN, Filippich LJ, Trott DJ. 2011. Risk factors for
463 dogs becoming rectal carriers of multidrug-resistant *Escherichia coli* during
464 hospitalization. Epidemiol Infect. 139:1511-21.
465 18. Ogeer-Gyles J, Mathews KA, Sears W, Prescott JF, Weese JS, Boerlin P. 2006.
466 Development of antimicrobial drug resistance in rectal *Escherichia coli* isolates
467 from dogs hospitalized in an intensive care unit. J Am Vet Med Assoc. 229:694-9.
468 19. Schmidt VM, Pinchbeck G, McIntyre KM, Nuttall T, McEwan N, Dawson S,
469 Williams NJ. 2018. Routine antibiotic therapy in dogs increases the detection of
470 antimicrobial-resistant faecal *Escherichia coli*. J Antimicrob Chemother. 73:3305-
471 3316.
472 20. Prescott JF, Boerlin P. 2016. Antimicrobial use in companion animals and Good
473 Stewardship Practice. Vet Rec. 179:486-488.
474 21. Wedley AL, Dawson S, Maddox TW, Coyne KP, Pinchbeck GL, Clegg P, Nuttall
475 T, Kirchner M, Williams NJ. 2017. Carriage of antimicrobial resistant *Escherichia*
476 *coli* in dogs: Prevalence, associated risk factors and molecular characteristics.

Vet Microbiol. 199:23-30.

22. Grønvold AM, L'abée-Lund TM, Sørum H, Skancke E, Yannarell AC, Mackie RI. 2010. Changes in fecal microbiota of healthy dogs administered amoxicillin. FEMS Microbiol Ecol. 71:313-26.

23. Leite-Martins LR, Mahú MI, Costa AL, Mendes A, Lopes E, Mendonça DM, Niza-Ribeiro JJ, de Matos AJ, da Costa PM. 2014. Prevalence of antimicrobial resistance in enteric *Escherichia coli* from domestic pets and assessment of associated risk markers using a generalized linear mixed model. Prev Vet Med. 117:28-39.

24. Schmidt VM, Pinchbeck GL, Nuttall T, McEwan N, Dawson S, Williams NJ. 2015. Antimicrobial resistance risk factors and characterisation of faecal *E. coli* isolated from healthy Labrador retrievers in the United Kingdom. Prev Vet Med. 119:31-40.

25. Baede VO, Wagenaar JA, Broens EM, Duim B, Dohmen W, Nijsse R, Timmerman AJ, Hordijk J. 2015. Longitudinal study of extended-spectrum-β-lactamase- and AmpC-producing Enterobacteriaceae in household dogs. Antimicrob Agents Chemother. 59:3117-24.

26. Day MJ, Horzinek MC, Schultz RD, Squires RA; Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). 2016. WSAVA Guidelines for the vaccination of dogs and cats. J Small Anim Pract. 57:E1-E45.

27. Costa D, Vinué L, Poeta P, Coelho AC, Matos M, Sáenz Y, Somalo S, Zarazaga M, Rodrigues J, Torres C. 2009. Prevalence of extended-spectrum beta-lactamase-producing *Escherichia coli* isolates in faecal samples of broilers. Vet Microbiol. 138:339-44.

502 28. Warren RE, Ensor VM, O'Neill P, Butler V, Taylor J, Nye K, Harvey M, Livermore
503 DM, Woodford N, Hawkey PM. 2008. Imported chicken meat as a potential
504 source of quinolone-resistant *Escherichia coli* producing extended-spectrum
505 beta-lactamases in the UK. J Antimicrob Chemother. 61:504-8.
506 29. Randall LP, Clouting C, Horton RA, Coldham NG, Wu G, Clifton-Hadley FA,
507 Davies RH, Teale CJ. 2011. Prevalence of *Escherichia coli* carrying extended-
508 spectrum β-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys
509 in Great Britain between 2006 and 2009. J Antimicrob Chemother. 66:86-95.
510 30. Radford AD, Noble PJ, Coyne KP, Gaskell RM, Jones PH, Bryan JG, Setzkorn C,
511 Tierney Á, Dawson S. 2011. Antibacterial prescribing patterns in small animal
512 veterinary practice identified via SAVSNET: the small animal veterinary
513 surveillance network. Vet Rec. 169:310.
514 31. Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-
515 Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP,
516 Avison MB. 2018. Prediction of Fluoroquinolone Susceptibility Directly from
517 Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass
518 Spectrometry to Identify Mutant Genotypes. Antimicrob Agents Chemother.
519 62:e01814-17.
520 32. Tchesnokova V, Radey M, Chattopadhyay S, Larson L, Weaver JL, Kisiela D,
521 Sokurenko EV. 2019. Pandemic fluoroquinolone resistant *Escherichia coli* clone
522 ST1193 emerged via simultaneous homologous recombinations in 11 gene loci.
523 Proc Natl Acad Sci U S A. 116:14740-14748.
524 33. Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP, Avison
525 MB. 2020. Characterization of cefotaxime-resistant urinary *Escherichia coli* from
526 primary care in South-West England 2017-18. J Antimicrob Chemother. 75:65-71.

34. Mounsey O, Schubert H, Findlay J, Morley K, Puddy EF, Gould VC, North P, Bowker KE, Williams OM, Williams PB, Barrett DC, Cogan TA, Turner KM, MacGowan AP, Reyher KK, Avison MB. 2021. Infrequent Sharing of Fluoroquinolone-Resistant *Escherichia coli* from Dairy Farms as a Cause of Bacteriuria in Humans Living in the Same Geographical Region. BioRxiv
35. Pightling AW, Pettengill JB, Luo Y, Baugher JD, Rand H, Strain E. 2018. Interpreting Whole-Genome Sequence Analyses of Foodborne Bacteria for Regulatory Applications and Outbreak Investigations. Front Microbiol. 9:1482.
36. Ewers C, Bethe A, Semmler T, Guenther S, Wieler LH. 2012. Extended-spectrum β-lactamase-producing and AmpC-producing *Escherichia coli* from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect. 18:646-55.
37. Gandolfi-Decristophoris P, Petrini O, Ruggeri-Bernardi N, Schelling E. 2013. Extended-spectrum β-lactamase-producing Enterobacteriaceae in healthy companion animals living in nursing homes and in the community. Am J Infect Control. 41:831-5.
38. Timofte D, Maciuca IE, Williams NJ, Wattret A, Schmidt V. 2016. Veterinary Hospital Dissemination of CTX-M-15 Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* ST410 in the United Kingdom. Microb Drug Resist. 22:609-615.
39. Murray JK, Kinsman RH, Lord MS, Da Costa REP, Woodward JL, Owczarczak-Garstecka SC, Tasker S, Knowles TG, Casey RA. 2021. 'Generation Pup' - protocol for a longitudinal study of dog behaviour and health. BMC Vet Res. 17:1.
40. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. Version

552 8.1.http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_ta
553 bles/v_8.1_Breakpoint_Tables.pdf.
554 41. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for
555 Illumina sequence data. Bioinformatics. 30:2114–2120.
556 42. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM,
557 Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler
558 G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly
559 algorithm and its applications to single-cell sequencing. J Comput Biol. 19:455–
560 477.
561 43. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics.
562 30:2068–2069.
563 44. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O,
564 Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial
565 resistance genes. J Antimicrob Chemother. 67:2640–2644.
566 45. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR,
567 Maiden MC, Ochman H, Achtman M. 2006. Sex and virulence in *Escherichia coli*:
568 an evolutionary perspective. Mol Microbiol. 60:1136–1151.
569 46. Grüning B, Dale R, Sjödin A, Chapman BA, Rowe J, Tomkins-Tinch CH, Valieris
570 R, Köster J; Bioconda Team. 2018. Bioconda: sustainable and comprehensive
571 software distribution for the life sciences. Nat Methods. 15:475–476.
572 47. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J, Poplawski R, Bull
573 MJ, Richardson E, Ismail M, Thompson SE, Kitchen C, Guest M, Bakke M,
574 Sheppard SK, Pallen MJ. 2016. CLIMB (the Cloud Infrastructure for Microbial
575 Bioinformatics): an online resource for the medical microbiology community.
576 Microb Genom. 2:e000086.

48. Stamatakis A, Ludwig T, Meier H. 2005. RAxML-III: a fast program for maximum likelihood-based inference of large phylogenetic trees. Bioinformatics. 21:456–463.

49. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics. 22:2688–2690.

50. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ, Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. Microb Genom. 2:e000093.

588 **Tables**

589

590 **Table 1.** Baseline data for all 16-week-old dogs (n=223) and associations with risk
591 factors for carriage of *E. coli* resistant to at least one test antibacterial. *p*-values were
592 calculated using the Pearson Chi-squared test (Stata/IC 15.1, StataCorp LLC,
593 College Station, TX, USA). The bold figures show a *p*-value < 0.05.

Risk factor from questionnaire	**Response to question**	**Response to question total (n=223)**	**Also resistant to at least one antibiotic (n=106)**	***p*-value**
Fed raw food	Yes	43	32/43	<0.001
	No	180	76/180	
Walked in town	Yes	181	84/181	0.21
	No	42	24/42	
Walked on farmland	Yes	142	69/142	0.95
	No	81	39/81	
Walked on beaches	Yes	103	52/103	0.57
	No	120	56/120	
Walked in the countryside	Yes	191	95/191	0.34
	No	32	13/32	
Walking near cattle	Yes	84	37/70	0.31
	No	139	71/139	
Swum/ paddled/ played in salt water	Yes	62	32/62	0.56
	No	161	76/161	
Swum/ paddled/ played in lake water	Yes	29	17/29	0.24
	No	194	91/194	
Swum/ paddled/ played in river water	Yes	66	33/66	0.76
	No	157	75/157	
Swum/ paddled/ played in pond water	Yes	65	38/65	0.06
	No	158	70/158	

594

595

596 **Table 2**. Univariable and multivariable logistic regression analyses using
597 questionnaire data and antibacterial-resistant *E. coli* data for 16-week-old dogs
598 (n=223). Presentation: Odds ratio (95% confidence interval) *p*-value. Only risk actors
599 significantly associated with resistance (*p*-value < 0.05) are included.

Risk Factor	Univariable (n=223)	Multivariable for all samples (n=223)
Resistance to at least one antibacterial (n=108)		
Fed raw food	3.98 (1.89 to 8.40) <0.001	3.98 (1.89 to 8.40) <0.001
Resistance to ciprofloxacin (n=26)		
Fed raw food	12.42 (5.01 to 30.78) <0.001	12.42 (5.01 to 30.78) <0.001
Resistance to tetracycline (n=81)		
Fed raw food	4.47 (2.21 to 9.05) <0.001	4.47 (2.21 to 9.05) <0.001
Resistance to amoxicillin (n=93)		
Fed raw food	3.30 (1.64 to 6.63) 0.001	3.18 (1.57 to 6.42) 0.001
Swam/paddled/ played in pond water	2.01 (1.12 to 3.61) 0.02	1.91 (1.05 to 3.48) 0.04
Resistance to cephalexin (n=34)		
No statistically significant risk factors identified		
Resistance to streptomycin (n=51)		
Fed raw food	8.23 (3.95 to 17.15) <0.001	8.23 (3.95 to 17.15) <0.001

600

601

602 **Table 3.** Characterisation of CTX-R *E. coli* from puppies using WGS. Stars denote

603 locally recruited dogs. Bold underlining denotes dogs fed raw food.

Dog ID	***E. coli* ST**	**FQ-R mechanism(s)**	**CTX-R mechanism**
DOG 1	ST372		CMY-2
DOG 2	ST10		CTX-M-1
DOG 3**	ST2179	*gyrA* S83L; *parC* S80I	CTX-M-65
DOG 4	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I	CTX-M-1
DOG 5	ST38	(*gyrA* S83L; *aac(6')-Ib-cr*)	CTX-M-15
DOG 6	ST58		*ampC* -42C>T
DOG 7	ST88		CTX-M-1
DOG 8	ST88		*ampC* -42C>T
DOG 9	ST38	(*qnrS1*)	CTX-M-15
DOG 10	ST963		CMY-2
DOG 11	ST1196	*gyrA* S83L; *gyrA* D87N; *parC* S80I; *qnrB4*	DHA-1
DOG 12	ST215	(*qnrS1*)	CTX-M-15
DOG 13	ST973		CMY-2
DOG 15	ST6096		CMY-2
DOG 16	ST3889	(*qnrS1*)	CTX-M-15
DOG 18	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I	CTX-M-1
DOG 21**	ST69	(*qnrS1*)	CTX-M-14
DOG 21**	ST963		CMY-2
DOG 22**	ST963		CMY-2
DOG 23	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I	CTX-M-1
DOG 25	ST155		*ampC* -42C>T
DOG 27	ST88	(*gyrA* S83L)	*ampC* -42C>T
DOG 27	ST1431	*gyrA* S83L; *gyrA* D87N; *parC* S80I; *qnrS1*	*ampC* -42C>T
DOG 28	ST602		*ampC* -42C>T
DOG 29	ST4988	*gyrA* S83L; *gyrA* D87N; *parC* S80I	CTX-M-15
DOG 31**	ST88		*ampC* -42C>T
DOG 42	ST1056		CTX-M-1
DOG 43	ST75		*ampC* -42C>T
DOG 44	ST961		CTX-M-1

604

605 **Table 4.** Characterisation of FQ-R *E. coli* from puppies using WGS. Stars denote

606 locally recruited dogs. Bold underlining denotes dogs fed raw food.

Dog ID	***E. coli* ST**	**FQ-R mechanism(s)**
DOG 4	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 9	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 10	ST224	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 14	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 16	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 17	ST453	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 17	ST58	*gyrA* S83L; *qnrS1*
DOG 17	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 18	ST224	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 19	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 20	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 21**	ST10	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 24	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 26	ST1196	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 26	ST1011	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 30	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 31**	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 32**	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 33	ST542	*gyrA* S83L; *parC* S80I
DOG 34	ST1011	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 34	ST6817	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 35	ST1011	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 35	ST224	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 36	ST155	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 37	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 37	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 38**	ST744	*gyrA* S83L; *gyrA* D87N; *parC* A56T; *parC* S80I
DOG 39**	ST162	*gyrA* S83L; *gyrA* D87N; *parC* S80I
DOG 40	ST1193	gyrA S83L; gyrA D87N; parC S80I; *parE* L416F
DOG 41**	ST1011	*gyrA* S83L; *gyrA* D87N; *parC* S80I

607

608 **Figure 1:** Core genome phylogenetic analysis of antibacterial-resistant *E. coli* from
609 puppies. CTX-R isolates are labelled red, FQ-R isolates are labelled green and CTX-
610 R/FQ-R dual-resistant isolates are labelled yellow. The randomly assigned Dog ID
611 relevant to each isolate is also labelled.



612